CYTR

CytRx Corporation Press Releases

$2.75
*  
0.03
1.08%
Get CYTR Alerts
*Delayed - data as of Sep. 19, 2014  -  Find a broker to begin trading CYTR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities Laws
9/16/2014 11:35:00 AM - Business Wire

Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
9/15/2014 3:23:00 PM - Business Wire

Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation
9/15/2014 9:01:00 AM - Business Wire

CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas
9/9/2014 6:00:00 AM - Business Wire

CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference
9/5/2014 6:00:00 AM - Business Wire

CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas
9/2/2014 6:00:00 AM - Business Wire

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire

Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology
8/7/2014 6:00:00 AM - Business Wire

CytRx Reports 2014 Second Quarter Financial Results
8/6/2014 6:00:00 AM - Business Wire

Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
6/30/2014 6:40:00 AM - PR Newswire

CytRx Added to Russell 3000® and Russell 2000® Indexes
6/30/2014 6:00:00 AM - Business Wire